4 news items
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
MREO
14 Jun 24
and their potential effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
MREO
RARE
11 Jun 24
be no assurance that future developments affecting Mereo BioPharma will be those that it anticipates. All of Mereo BioPharma's forward-looking
Mereo BioPharma to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
MREO
3 Apr 24
are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
MREO
27 Mar 24
as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates. All
- Prev
- 1
- Next